Form 4 Moderna, Inc. For: Feb 22 Filed by: Hoge Stephen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Moderna (MRNA) downgraded as HSBC skeptical on medium term INT Phase 3 data readouts
February 26, 2024 9:33 AM ESTHSBC analysts cut Moderna (NASDAQ: MRNA) to Reduce from Hold in a note Monday, raising the price target to $86 from $75 per share.
The firm said Moderna's outlook for 2024 is underpinned by prospects for its COVID-19 vaccine revenue and RSV launch. They note there are two... More
